On Monday, Spyre Therapeutics Inc (NASDAQ: SYRE) was 4.59% up from the session before settling in for the closing price of $15.69. A 52-week range for SYRE has been $10.91 – $40.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 44.65% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 2.86%. With a float of $51.32 million, this company’s outstanding shares have now reached $60.28 million.
In an organization with 65 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Spyre Therapeutics Inc (SYRE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 14.97%, while institutional ownership is 99.30%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.28% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.30 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.52 million. That was inferior than the volume of 0.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.18%.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 45.35%, which indicates a significant decrease from 73.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.14 in the past 14 days, which was lower than the 1.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.48, while its 200-day Moving Average is $21.64. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $16.77. Second resistance stands at $17.14. The third major resistance level sits at $17.72. If the price goes on to break the first support level at $15.83, it is likely to go to the next support level at $15.25. Assuming the price breaks the second support level, the third support level stands at $14.88.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are 60,276K outstanding shares of the company, which has a market capitalization of 990.40 million. As of now, sales total 0 K while income totals -208,020 K. Its latest quarter income was 0 K while its last quarter net income were -44,770 K.
